Ofatumumab (Arzerra) - Oncology Nurse Advisor

Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide

This slideshow reviews ofatumumab (Arzerra), indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab (Campath).

Topics:

Chronic Lymphocytic Leukemia Hematologic Cancers Slideshows Stat Consult

Next hm-slideshow in Slides

Vincristine